A comparison of vaginal misoprostol and vaginal evening primrose oil

A comparison of vaginal misoprostol and vaginal evening primrose oil in first trimester termination

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201218049749N1

Enrollment

Registered

2021-02-05

Start date

2019-07-23

Completion date

Unknown

Last updated

2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Spontaneous abortion. Genital tract and pelvic infection following incomplete spontaneous abortion

Interventions

Intervention 1: First intervention group : The effect of vaginal misoprostol, with Iranian brand and made in Iran, whose effective ingredient is 200 micrograms. Initial dose Initially 600 micrograms (

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Pregnant women go to Beheshti Hospital for up to 14 weeks to terminate their pregnancy

Exclusion criteria

Exclusion criteria: Uncontrolled seizures Uncontrolled blood pressure Chronic lung disease Mitral valve stenosis History of known allergy to prostaglandin E1 Inflammatory bowel disease Sensitivity to evening primrose Coagulation disease Schizophrenia and phenothiazine use Cone biopsy of the cervix Smoking and supplements

Design outcomes

Primary

Measure	Time frame
Spontaneous abortion. Timepoint: First and 6 hours and 12 hours after taking the drug. Method of measurement: Complete disposal of pregnancy products.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Mousavi Shirazi

Kashan University of Medical Sciences

pegahmousavi60@gmail.com+98 31 5555 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026